Third Harmonic Bio Inc. Total Liabilities
Third Harmonic Bio Inc. total liabilities. Based on the latest financial reports, Third Harmonic Bio Inc. (THRD) has total liabilities worth $7.21 Million USD as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See THRD days of operational coverage to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Third Harmonic Bio Inc. (2020–2024)
Total liabilities of Third Harmonic Bio Inc. from 2020 to 2024. This chart illustrates how Third Harmonic Bio Inc.'s total liabilities have evolved over time, based on quarterly financial data.
Third Harmonic Bio Inc. Competitors by Total Liabilities
The table below lists competitors of Third Harmonic Bio Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
VT GMP Co.Ltd
KQ:018290
|
Korea | ₩93.15 Billion |
|
J&V Energy Tech Co Ltd
TW:6869
|
Taiwan | NT$10.66 Billion |
|
Eisen- und Hüttenwerke AG
F:EIS
|
Germany | €2.12 Million |
|
Trigold Holdings Ltd
TWO:3709
|
Taiwan | NT$21.32 Billion |
|
ODFJELL TECHNOLOGYLTD
F:ND4
|
Germany | €3.09 Billion |
|
Hainan Yedao Group Co Ltd
SHG:600238
|
China | CN¥742.70 Million |
|
Guangdong Tengen Industrial Group C
SHE:003003
|
China | CN¥473.49 Million |
|
Jahwa Electron
KO:033240
|
Korea | ₩318.87 Billion |
Liability Composition Analysis (2020–2024)
This chart breaks down Third Harmonic Bio Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Third Harmonic Bio Inc..
Liquidity & Leverage Metrics
Third Harmonic Bio Inc. Total Liabilities Ratios Explained
Third Harmonic Bio Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 54.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.03 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Third Harmonic Bio Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Third Harmonic Bio Inc. (2020–2024)
The table below shows the annual total liabilities of Third Harmonic Bio Inc. from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $9.46 Million | +9.65% |
| 2023-12-31 | $8.63 Million | -10.21% |
| 2022-12-31 | $9.61 Million | -94.54% |
| 2021-12-31 | $175.87 Million | +556.48% |
| 2020-12-31 | $26.79 Million | -- |
About Third Harmonic Bio Inc.
Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It also develops THB335, an oral small molecule KIT inhibit… Read more